Understanding how HDAC6 affects breast cancer treatment responses
Investigating the Molecular Determinants Driving Response and Resistance to HDAC6 Targeted Therapy in Breast Cancer
This study is looking at how a protein called HDAC6 affects breast cancer treatment, hoping to find out which patients might do better with new therapies that target this protein, so they can get more effective care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11049020 on NIH RePORTER |
What this research studies
This research investigates the role of histone deacetylase 6 (HDAC6) in breast cancer, focusing on how it influences the effectiveness of targeted therapies. By analyzing a large number of breast cancer samples, the researchers have identified a biomarker that helps determine which patients may benefit from HDAC6-targeted treatments. The study aims to improve treatment strategies by exploring the molecular mechanisms behind the anticancer effects of HDAC6 inhibitors in combination with other therapies. Patients with specific breast cancer profiles may be eligible for clinical trials testing these innovative treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with breast cancer who have tumors that depend on HDAC6 for their growth.
Not a fit: Patients with breast cancer that does not rely on HDAC6 or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with certain types of breast cancer.
How similar studies have performed: Previous research has shown promising results with HDAC6 inhibitors in breast cancer, indicating potential for success in this approach.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Silva, Jose M — Icahn School of Medicine at Mount Sinai
- Study coordinator: Silva, Jose M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.